{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:09:39Z","timestamp":1773403779811,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.neuropharm.2006.08.025","type":"journal-article","created":{"date-parts":[[2006,10,15]],"date-time":"2006-10-15T10:45:08Z","timestamp":1160909108000},"page":"542-551","source":"Crossref","is-referenced-by-count":57,"title":["Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats"],"prefix":"10.1016","volume":"52","author":[{"given":"Elizabeth","family":"Hohnadel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Alvin V.","family":"Terry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neuropharm.2006.08.025_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","article-title":"Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia","volume":"18","author":"Aarsland","year":"2003","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"12","key":"10.1016\/j.neuropharm.2006.08.025_bib2","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1176\/ajp.150.12.1856","article-title":"Normalization of auditory physiology by cigarette smoking in schizophrenic patients","volume":"150","author":"Adler","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.08.025_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.schbul.a033320","article-title":"Schizophrenia, sensory gating, and nicotinic receptors","volume":"24","author":"Adler","year":"1998","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neuropharm.2006.08.025_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0306-4522(02)00234-8","article-title":"Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis","volume":"114","author":"Ballmaier","year":"2002","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuropharm.2006.08.025_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00002512-200421010-00004","article-title":"Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study","volume":"21","author":"Boada-Rovira","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2006.08.025_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2006.08.025_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0920-9964(01)00387-5","article-title":"An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia","volume":"59","author":"Buchanan","year":"2003","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2006.08.025_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","article-title":"Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series","volume":"18","author":"Bullock","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.neuropharm.2006.08.025_bib9","first-page":"165","article-title":"Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate","volume":"19","author":"Chez","year":"2004","journal-title":"J. Child Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2006.08.025_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0006-3223(00)00918-5","article-title":"Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation","volume":"48","author":"Crook","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2006.08.025_bib11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.158.6.918","article-title":"Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment","volume":"158","author":"Crook","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.neuropharm.2006.08.025_bib12","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/sj.npp.1300761","article-title":"Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice","volume":"30","author":"Csernansky","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2006.08.025_bib13","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington's disease","volume":"19","author":"de Tommaso","year":"2004","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neuropharm.2006.08.025_bib14","first-page":"54","article-title":"The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia","volume":"1","author":"Dean","year":"1996","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.08.025_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-3223(01)01342-7","article-title":"A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia","volume":"51","author":"Friedman","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.08.025_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-004-1794-x","article-title":"Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists","volume":"174","author":"Friedman","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.neuropharm.2006.08.025_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-005-2235-1","article-title":"Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial","volume":"181","author":"Freudenreich","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.neuropharm.2006.08.025_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brainres.2004.11.042","article-title":"Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits","volume":"1033","author":"Geerts","year":"2005","journal-title":"Brain Res."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2006.08.025_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.neuropharm.2006.08.025_bib20","first-page":"175","article-title":"Lead-stimulation effects of human cardiac orienting and blink reflexes","volume":"104","author":"Graham","year":"1975","journal-title":"J. Exp. Psychol. Hum. Percept. Perform."},{"issue":"Suppl. 6","key":"10.1016\/j.neuropharm.2006.08.025_bib21","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/S1525-8610(04)70409-0","article-title":"Cholinesterase inhibitors in non-Alzheimer dementias","volume":"4","author":"Gustavson","year":"2003","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"3","key":"10.1016\/j.neuropharm.2006.08.025_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/104454602760386923","article-title":"A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder","volume":"12","author":"Hardan","year":"2002","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2006.08.025_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/jpet.105.093047","article-title":"Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats","volume":"316","author":"Hernandez","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2006.08.025_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2190\/JE5Q-1NFT-FL40-7PMW","article-title":"Galantamine in the treatment of adult autism: a report of three clinical cases","volume":"33","author":"Hertzman","year":"2003","journal-title":"Int. J. Psychiatry Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2006.08.025_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.104.075887","article-title":"Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats","volume":"312","author":"Jones","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.neuropharm.2006.08.025_bib26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0022-3565(24)39166-9","article-title":"Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex","volume":"294","author":"Jones","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2006.08.025_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/hup.286","article-title":"Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia","volume":"16","author":"Kumari","year":"2001","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2006.08.025_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00213-002-1099-x","article-title":"Effects of typical and atypical antipsychotics on\u00a0prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research","volume":"162","author":"Kumari","year":"2002","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2006.08.025_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00002826-200311000-00011","article-title":"Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia","volume":"26","author":"Lenzi","year":"2003","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2006.08.025_bib30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-3223(00)01109-4","article-title":"Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease","volume":"49","author":"Maelicke","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2006.08.025_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0893-133X(89)90035-3","article-title":"Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat","volume":"2","author":"Mansbach","year":"1989","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2006.08.025_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00212846","article-title":"Dopaminergic stimulation disrupts sensorimotor gating in the rat","volume":"94","author":"Mansbach","year":"1988","journal-title":"Psychopharmacology (Berl.)"},{"issue":"4","key":"10.1016\/j.neuropharm.2006.08.025_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/gps.826","article-title":"The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure","volume":"18","author":"Mintzer","year":"2003","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2006.08.025_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.105.087908","article-title":"Modulation of N-methyl-d-aspartate receptors by donepezil in rat cortical neurons","volume":"315","author":"Moriguchi","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2006.08.025_bib35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00213-006-0307-5","article-title":"A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia","volume":"184","author":"Postma","year":"2006","journal-title":"Psychopharmacology (Berl.)."},{"issue":"3","key":"10.1016\/j.neuropharm.2006.08.025_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/oxfordjournals.schbul.a033330","article-title":"Postmortem studies in schizophrenia","volume":"24","author":"Powchik","year":"1998","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.neuropharm.2006.08.025_bib37","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/sj.npp.1300210","article-title":"Central muscarinic acetylcholine receptor availability in patients treated with clozapine","volume":"28","author":"Raedler","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2006.08.025_bib38","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2006.08.025_bib39","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pnpbp.2005.10.017","article-title":"Chronic nicotine interactions with clozapine and risperidone and attentional function in rats","volume":"30","author":"Rezvani","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2006.08.025_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2003.12.021","article-title":"Nicotine\u2013antipsychotic drug interactions and attentional performance in female rats","volume":"486","author":"Rezvani","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.08.025_bib41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2006.04.006","article-title":"Galantamine improves cognition in schizophrenic patients stabilized on risperidone","volume":"60","author":"Schubert","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.08.025_bib42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.schres.2006.03.037","article-title":"Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation","volume":"85","author":"Sharma","year":"2006","journal-title":"Schizophr. Res."},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2006.08.025_bib43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0028-3908(94)90074-4","article-title":"Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats","volume":"33","author":"Sipes","year":"1994","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2006.08.025_bib44","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.neuropharm.2006.08.025_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00002826-200301000-00004","article-title":"Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia","volume":"26","author":"Stryjer","year":"2003","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2006.08.025_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1749-6632.1999.tb09269.x","article-title":"Cross-species studies of sensorimotor gating of the startle reflex","volume":"877","author":"Swerdlow","year":"1999","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2006.08.025_bib47","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s002130100799","article-title":"Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges","volume":"156","author":"Swerdlow","year":"2001","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2006.08.025_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1527-3458.2005.tb00045.x","article-title":"Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition","volume":"11","author":"Terry","year":"2005","journal-title":"CNS Drug Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2006.08.025_bib49","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390806003042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390806003042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T14:19:03Z","timestamp":1736605143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390806003042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0028390806003042"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2006.08.025","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}